The systemic degradation of bone mass, strength, and microarchitecture that characterises osteoporosis, which raises the risk of fragility fractures, is an increasing medical and socioeconomic hazard. It has been demonstrated that Embelin (2, 5-dihydroxy-3-undecyl-1,4-benzoquinone) inhibits the NF-kB cell signalling pathway, hence suppressing osteoclast genesis brought on by receptor activator of NF-kB ligand (RANKL) and tumour cells in vitro. Osteoporosis treatment or prevention may involve the use of embelin. The goal of the current study was to evaluate how embelin, a substance derived from Embelia ribes berries, affected rats with osteoporosis brought on by ovariectomy. The results indicate that embelin has anti-osteoporotic properties against ovariectomy-induced osteoporosis in female rats. A 90-day embelin treatment improved bone biochemical quality by altering trabecular microarchitecture without having a hyperplasic effect on the uterus, and it may be a potential medication for the prevention and treatment of postmenopausal osteoporosis. It also reduced body weight gain and stopped bone loss caused by ovariectomy, and there was a significant reduction in skeletal remodeling, as shown by t-score measurements.

Key words: Ovariectomy, embelia Ribes, embelin, osteoporosis and body weight.